Financial Times Highlights: AstraZeneca Vaccine Move, Alzheimer's Drug Cost, Nestlé CEO Change

This briefing covers significant developments in the business world, including AstraZeneca's potential relocation, the UK approval yet NHS rejection of an Alzheimer's drug, Nestlé's CEO transition, Gatwick Airport's growth, and Deutsche Bank's settlements in the Postbank case.

AstraZeneca has issued a warning that it may transfer its UK vaccine manufacturing unit to Philadelphia. This comes amid a standoff with the UK Labour government over plans to diminish state aid for the project.

An innovative Alzheimer's drug, approved by UK regulators, will not be offered to NHS patients due to cost concerns, despite its potential to slow disease progression.

In corporate news, Nestlé has announced the departure of its CEO, Mark Schneider. He will be succeeded by Laurent Freixe, a seasoned company veteran, following a notable period of underperformance.

Gatwick Airport is on track for a record summer, driven by pent-up demand for travel and new long-haul routes, resulting in nearly 8% passenger growth in the first half of the year.

Deutsche Bank has resolved disputes with 60% of claimants in its prolonged legal battle over the acquisition of Postbank, marking a significant step towards ending the over decade-long litigation.